Gland Pharma Ltd.

₹2,517

-26.7 (-1%)

GLAND Share Price

Pharmaceuticals & Biotechnology

As on July 30, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 41,603 Cr

P/E Ratio59.37

Dividend Yield0.72 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,459.18	Bullish
10-DMA	2,450.32	Bullish
20-DMA	2,468.37	Bullish
50-DMA	2,360.44	Bullish
100-DMA	2,059.02	Bullish
200-DMA	1,927.57	Bullish

Historical Performance

1 Year

22.1%

3 Years

94.8%

5 Years

-36%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	56,165	56,647	36,246	44,007	34,629
Total Expenditure	43,476	43,316	25,998	28,906	21,606
Other Income	2,136	1,702	2,405	2,239	1,348
Operating Profit	14,825	15,033	12,652	17,341	14,370
Interest	420	262	74	52	34
Depreciation	3,779	3,446	1,467	1,103	988
Profit Before Tax	10,627	11,325	10,546	16,186	13,348
Consolidated Net Profit	6,985	7,725	7,810	12,117	9,970
Adjusted EPS	42	47	47	74	61

Compounded Sales Growth

10 Years:16.4

5 Years:16.4

3 Years:5

TTM:-0.2

Compounded Profit Growth

10 Years:-2

5 Years:-2

3 Years:-10.4

TTM:-2

Stock Price CAGR

10 Years:N/A

5 Years:-8.5

3 Years:24.4

TTM:21.9

Return on Equity

10 Years:N/A

5 Years:60.9

3 Years:47.4

last year:42.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	165	165	165	164	164
Total Reserves	91,342	87,060	79,406	71,280	58,615
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	4,573	4,886	897	940	803
Other Current Liabilities	6,199	5,201	1,095	764	624
Short Term Borrowings	---	---	---	---	---
Total Liabilities	1,11,729	1,06,108	87,775	78,336	64,961
Capital Work in Progress	1,506	2,379	1,772	1,807	3,378
Long Term Loans & Advances	877	1,194	1,290	2,864	780
Currents Investments	---	---	---	1,549	---
Short Term Loans and Advances	8,751	4,892	2,224	2,465	876
Total Current Assets	67,829	56,452	69,008	58,521	51,236
Total Assets	1,11,729	1,06,108	87,775	78,336	64,961
Adjusted Book Value	555	530	483	435	359

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 59.37, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 24.4%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹14825 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹56165 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1219004.3

No. of Shares: 484 (Approx)

Performance:21.9%

219004.3

NIFTY Performance: -1.8%

1 day Top Gainers